Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rejects Noven Fentanyl Patch ANDA Due To Safety Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will cease reviewing Noven/Endo’s generic version of J&J’s Duragesic chronic pain therapy due to a higher drug content in the pending ANDA.

You may also be interested in...



Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA

Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.

Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA

Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.

Duragesic Public Health Advisory Follows Palladone Withdrawal

FDA is investigating reports of deaths associated with overdoses of the fentanyl patch (J&J’s Duragesic and generics). As with Purdue’s opioid Palladone, alcohol consumption is cited as a possible factor in increased fentanyl release or effect.

Related Content

Topics

UsernamePublicRestriction

Register

PS062959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel